• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure inks Chinese collaborative deal with Zai Lab

September 12, 2018 By Fink Densford

Novocure

Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region.

The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication.

Through the agreement, Novocure granted Zai Labs an exclusive licensing agreement to commercialize TTF in China, Hong Kong, Macau and Taiwan. Zai Lab will be responsible for regulatory submissions in Greater China and will promote the TTF technology in the region, Novocure said.

“The Zai Lab team is passionate about bringing innovative treatments to patients in need, a passion we share at Novocure. We believe this collaboration supports our mission of making Tumor Treating Fields available to patients throughout the world and will accelerate the development of Tumor Treating Fields in indications beyond glioblastoma,” exec hair Bill Doyle said in a prepared statement.

Novocure said that while its Optune TTF device is not yet approved for commercialization in China, the technology was recommended with Level 1 evidence as a treatment for glioblastoma in China’s Glioma Treatment Guideline published in 2016.

“There are approximately 45,000 newly diagnosed GBM patients annually in China. Temozolomide is currently the only approved therapy for GBM in China so there are limited choices for one of the most deadly cancers. I am eagerly anticipating Tumor Treating Fields approval in China,” China National Cancer Center associate director Lvhua Wang said in a press release.

As part of the deal, Novocure will receive $15 million up front and is eligible for milestone payments and royalties on products sold in the Greater China region.

“Optune has demonstrated strong efficacy in a very challenging and difficult to treat cancer, GBM. Optune was approved in Japan without the need for a local bridging trial and we hope for similar rapid development in China. In addition, Tumor Treating Fields has the potential to treat a variety of solid tumors, which we believe are complementary to Zai Lab’s existing late-stage oncology assets and represent strong commercial synergy for us,” Zai Lab CEO Dr. Samantha Du said in prepared remarks.

Earlier this month, NovoCure released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival.

Filed Under: Business/Financial News, Oncology Tagged With: NovoCure

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS